FASENRA approved for treatment of children aged 6 to 11 with severe asthma
AstraZeneca steps up to show Fasenra helping patients step out
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
AstraZeneca is refreshing its Fasenra campaign. Almost six years into the launch, the Big Pharma has established consistent messaging across physicians and patients for the first time, tying the brand to the line “Move Forward With Fasenra” as it seeks to drive growth of the blockbuster asthma drug.
Eosinophilic esophagitis (EoE) is a rare, progressive, chronic inflammatory disease of the esophagus currently believed to be characterised by the abnormal presence of eosinophils, a type of white blood cell, in the inner lining of the esophagus.1-3 Patients experience difficulty with swallowing (dysphagia), pain, food getting stuck and anxiety.4,5
March 14 (Reuters) - AstraZeneca Plc (AZN.L) said on Monday the U.S. drug regulator declined to approve its asthma medicine, Fasenra, for treatment of chronic rhinosinusitis with nasal polyps, a condition characterised by benign growths that cause pain and stuffiness.
The FDA on Monday approved a 40 mg prefilled syringe of Nucala for certain kids between 6 and 11 years old, meaning they can take the drug at home instead of trekking to the doctor’s office every four weeks. That makes a big difference for children with severe eosinophilic asthma (SEA), who may have trouble fitting in appointments around school and caregivers’ jobs, GSK’s US senior medical lead Tom Corbridge told Endpoints News.
AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinophilic gastritis (EG), with or without eosinophilic gastroenteritis (EGE).
AstraZeneca announced on Thursday that the first patients had been dosed in the Phase III Fasenra (benralizumab) clinical trial in bullous pemphigoid (BP), and in two Phase II trials in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU), bringing the total of clinical trials into the drug up to ten.